Sema4 announces changes to its Research & Development

0

Founder Eric Schadt leaves the organization, including his role as President and Head of R&D

Matthew Davis named chief technology and product officer to continue driving youthe company’s mission to unlock insights from data, leading to healthier lives

STAMFORD, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) — Sema4, a health information company, today announced changes to its research and development (R&D) leadership. Founder Eric Schadt is stepping down as President and Head of R&D, as well as his position on the Board of Directors, effective immediately. Matthew Davis, PhD, who will serve as chief technology and product officer, will join the company’s R&D organization and leadership team.

Dr. Davis brings over 20 years of experience in enterprise product and technology development, including significant expertise in the field of genomics. He will work closely with Sema4 Chief Scientific Officer, Gustavo Stolovitzky, who is responsible for research initiatives, driving scientific and product innovation, and implementing data and artificial intelligence strategy. (IA) of the company for health system and biopharmaceutical partners.

“Eric’s departure from Sema4 marks the start of a new chapter for the company. I want to thank Eric for his contributions to Sema4 over the years,” Ms. Stueland said. “Eric’s vision was instrumental in bringing Sema4 to where it is today. We wish him good luck in all his future endeavours.

Ms. Stueland continued, “I am delighted to welcome Matt to our leadership team, especially as we enter a new phase of commercial scale fueled by customer-centric scientific innovation. Matt has a proven track record of bringing cutting-edge technology products and applications to market, which will allow us to better meet the needs of healthcare providers and patients. His leadership and insight into harnessing innovation will play a key role in delivering essential offerings to ultimately realize a future where precision medicine is truly the standard of care.

Dr. Davis was most recently Head of AI and Data at Invitae Corp., where he led strategy development and supported the engineering organization in applying AI to problems in genetics, d and decision support tools for internal and external customers. He also led the unification of product and technology strategy following key acquisitions made by Invitae.

Previously, Dr. Davis served as a group leader at IBM Research, where he oversaw the research and development of enterprise product platforms and applications to facilitate human interaction with computer systems. AI. While at IBM Research, his academic research leveraged AI and machine learning methods to solve user problems in social computing, personalization and recommendation systems. Dr. Davis has published a significant amount of academic research on computer science and genetics.

“Sema4 has an exceptional reputation for scientific excellence and data-driven health intelligence,” said Dr. Davis. “I look forward to joining this incredibly talented team to help us drive our product strategy and roadmap, and also to introduce new technology processes that can further accelerate the insights we deliver to patients, healthcare systems and to pharmaceutical partners.

About Sema4
Sema4 is a patient-centric health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 transforms healthcare by applying AI and machine learning to multi-dimensional, longitudinal clinical and genomic data to build dynamic models of human health and define optimal, individualized health trajectories. Centrellis™, our innovative health intelligence platform, enables us to generate a more comprehensive understanding of disease and well-being and provide science-based solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners and data should be shared for the benefit of all.

For more information, visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and YouTube.

Contact with Investor Relations:
Joel Kaufman
[email protected]

Media Contact:
Radley Moss
[email protected]

Share.

About Author

Comments are closed.